Canadian International Pharma Corp. Announces Non-Brokered Private Placement
2489 Bellevue Avenue, West Vancouver, BC Canada V7V 1E1 . Tel 604.922.2030 . Fax 604.922.2037
News Release No: 17-02
Trading symbols: TSX-V - NEX: CIP.H
Canadian International Pharma Corp. Announces
Non-Brokered Private Placement
West Vancouver, British Columbia, May 24, 2017 – Canadian International Pharma Corp. (the “Company” or
“CIPC”) announces that, subject to regulatory approval, the Company intends to proceed with a non -brokered
private placement to raise up to $500,000 by the issuance of 10,000,000 units (the “Units”) at $0.05 per Unit. Each
Unit will consist of one common share and one share purchase warrant, with each warrant entitling the holder to
purchase an additional common share for a period of one year at an exercise price of $0.10. With respect to this
private placement, the Company may pay finders’ fees in the amount of 10% (payable in cash or Units), based on
the sale of the Units purchased by subscribers introduced to the Company by such finders.
The Company intends to use the proceeds f rom this private placement for financing the continued development
and pursuit of business opportunities in the area of pharmaceutical and neutraceutical manufacturing and
distribution and for general working capital purposes.
About Canadian International Pharma Corp.
Canadian International Pharma Corp. (“CIPC” or the “Company”) is an emerging multi -faceted pharmaceutical
company that is in the process of developing generic and nutraceutical drug manufacturing, distribution and sales.
CIPC has recently launched its PharmaCert Program. PharmaCert is a certification program for testing and
measuring finished dosage forms of nutraceutical and pharmaceutical medications. The Company has also aligned
itself with Canadian and US manufacturers with the objective of manufacturing generics and nutraceuticals for
Canadian and overseas markets.
For further information, contact Mr. Clive Shallow, Shareholder Communications, at 604-922-2030, or visit the Company’s
website at www.canpharmacorp.ca.
CANADIAN INTERNATIONAL PHARMA CORP.
“Douglas L. Mason”
____________________________________________
Douglas L. Mason, Chief Executive Officer
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX Venture
Exchange) accepts responsibility for the adequacy of accuracy of this release.
FORWARD-LOOKING STATEMENTS
This release includes certain statements that may be deemed “forward-looking statements” within the meaning of applicable
securities legislation. All statements, other than statements of historical facts, that address such matters, including the finder’s
fee that may be paid by the Company and the intended use of proceeds of the private placem ent, are forward -looking
statements. Forward-looking statements are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “suspects”, “intends”, “estimates”, “projects”, ”targets”, “potential” and similar express ions, or that events or
conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such
2489 Bellevue Avenue, West Vancouver, BC Canada V7V 1E1 . Tel 604.922.2030 . Fax 604.922.2037
forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance
and actual results may differ mate rially from those expressed in, or implied by, this forward-looking information. Factors that
could cause actual results to differ materially from those in forward -looking statements include such matters as market prices
for the Company’s anticipated products, regulatory approvals required for the Company’s business plans, continued availability
of capital and financing, and general economic, market or business conditions. Any forward-looking statements are expressly
qualified in their entirety by this cautionary statement. Forward-looking statements are based on the beliefs, estimates and
opinions of the Company’s management on the date such statements were made and are subject to change after that date
and the Company does not undertake any obligation to update publicly or revise any forward-looking statements, whether as
a result of new information, future events or otherwise, except as may be required by applicable securities laws.
This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein in the
United States. The securities described herein have not been and will not be registered under the United States Securities Act
of 1933, as amended, and may not be offered or sold in the United States or to the account or benefit of a U.S. person absent
an exemption from the registration requirements of such Act.